Teva's new EU antitrust probe into its blockbuster multiple sclerosis drug breaks fresh legal ground for the European Commission, seeing it take on patent filing tactics and a suspected campaign to disparage rival drugs. While national watchdogs have looked into similar conduct before, it’s a first for the EU enforcer and, if